In plain terms: Vascanox HP (Nitric Oxide / Noxa24) has not yet been tested in a human trial designed to measure the outcome relevant here. The available human research does not yet answer the question.
Vascanox HP (Nitric Oxide / Noxa24)
The evidence as the record states it
Houston et al. (Cureus, 2023; PMID 37849591): open-label, uncontrolled, 12 adults with elevated blood pressure or mild hypertension, 4 weeks, no placebo and no blinding. Systolic pressure fell about 11 mmHg; diastolic pressure fell about 11 mmHg in the participants with raised diastolic pressure and not in those whose diastolic pressure was normal. The authors' conclusion that the product is safe, effective, quick-acting and long-lasting is not something an uncontrolled 4-week study of 12 people can show. Funding: one author is on the staff of Calroy Health Sciences, which sells the product tested, and the authors declare a United States patent application and an international application covering the composition; the indexed record names no funder. D Route 1: no randomized trial of this formula, one open-label study, no control arm, no replication.
Why Grade D Route 1 and not Grade C
Grade D Route 1 applies when no qualifying human randomized trial has tested this compound or intervention against the relevant endpoint. Absence confirmed: Vascanox OR Noxa24 OR (S-allylcysteine AND nitrate) AND randomized controlled trial[pt] AND (blood pressure OR hypertension) (PubMed, October 2026)
The first qualifying human RCT with a meaningful endpoint would move this to Grade C or higher, depending on what it shows.
What would move this grade
The first qualifying randomized controlled trial in humans, testing this intervention against a meaningful aging-relevant endpoint, would initiate grading. Depending on the result, it could land at any grade from A to D.